{"id":209638,"name":"INNOVATIVE VACCINE TECHNOLOGIES","slug":"innovative-vaccine-technologies","state":"UT","country":"United States of America","description":"Bio tech company","totalSpending":810000,"filings":20,"yearlySpending":[{"year":2021,"income":180000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":120000},{"year":2025,"income":30000}],"issues":[{"code":"MED","display":"Medical/Disease Research/Clinical Labs"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["THE LIVINGSTON GROUP, LLC"],"lobbyists":["PAUL CAMBON","ROBERT LIVINGSTON","J MARTIN","BRIAN GLACKIN"],"govEntities":["Army, Dept of (Other)","Defense, Dept of (DOD)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["FY '22 Appropriations for clinical trials for new vaccine platform","FY '22 Appropriations for clinical trials for new vaccine platform","FY2022 Appropriation for the development of a synthetic vaccine","H.R.___ S.___ FY 2022 Defense Appropriations Bill\nFY 2022 appropriations for the development of a synthetic vaccine","FY2022 Appropriation for the development of a synthetic vaccine"]}